ScholarLens Back to search
2014•KanzoOpen access

Cyberknife, stereotactic body radiation therapy for hepatocellular carcinoma

Yusuke Ohkubo, Hiroyuki Makino, Yuta Ochi, Kojiro Kobayashi, Yuta Suzuki, Kazuhiro Fuchinoue, Masataka Yoneda, Takeshi Kenmochi, Kazue Shiozawa, Takayuki Mori, Wataru Yamamuro

Open full text 1 citations

Abstract

We evaluated local control of hepatocellular carcinoma (HCC) treated with Cyberknife, stereotactic body radiation therapy (SBRT). CyberKnife, SBRT system with real-time tumor tracking has good efficacy and low toxicity.54 patients with 67 liver-confined HCC were treated with Cyberknife. Fiducials were implanted in the liver before treatment and were used as markers to track the lesion's movement. A total dose of 30 to 60 Gy in three fractions was prescribed to the 80%isodose line. Treatment response was evaluated by RECICL, CR: 82%, PR: 16%, PD: 2%. The local control rate was 92.3%at 1 year. Cyberknife was a safe, effective, noninvasive option for patients with HCC.

Open-access reader

About this research paper

What this paper is about

We evaluated local control of hepatocellular carcinoma (HCC) treated with Cyberknife, stereotactic body radiation therapy (SBRT). CyberKnife, SBRT system with real-time tumor tracking has good efficacy and low toxicity.54 patients with 67 liver-confined HCC were treated with Cyberknife. Fiducials were implanted in the liver before treatment and were used as markers to track the lesion's movement. A total dose of 30 to 60 Gy in three fractions was prescribed to the 80%isodose line. Treatment response was evaluated by RECICL, CR: 82%, PR: 16%, PD: 2%. The local control rate was 92.3%at 1 year. Cyberknife was a safe, effective, noninvasive option for patients with HCC.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

We evaluated local control of hepatocellular carcinoma (HCC) treated with Cyberknife, stereotactic body radiation therapy (SBRT). CyberKnife, SBRT system with real-time tumor tracking has good efficacy and low toxicity.54 patients with 67 liver-confined HCC were treated with Cyberknife. Fiducials were implanted in the liver before treatment and were used as markers to track the lesion's movement. A total dose of 30 to 60 Gy in three fractions was prescribed to the 80%isodose line. Treatment response was evaluated by RECICL, CR: 82%, PR: 16%, PD: 2%. The local control rate was 92.3%at 1 year. Cyberknife was a safe, effective, noninvasive option for patients with HCC.

Key concepts: Cyberknife, Medicine, Hepatocellular carcinoma, Fiducial marker, Nuclear medicine, Radiation therapy, Radiology, Stereotactic radiation therapy

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Cyberknife, stereotactic body radiation therapy for hepatocellular carcinoma — Research Paper | ScholarLens